- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.01. | This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday | 16 | Benzinga.com | ||
| 28.01. | CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis | 10 | Benzinga.com | ||
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 28.01. | CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern' | 1 | FierceBiotech | ||
| 28.01. | CalciMedica-Aktie bricht nach Studienabbruch zu Nierenversagen um 80 % ein | 8 | Investing.com Deutsch | ||
| 28.01. | CalciMedica discontinues AKI trial following safety concerns | 1 | Investing.com | ||
| 28.01. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.01. | CalciMedica, Inc.: CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation | 690 | PR Newswire | Safety concern warrants reevaluation of study design, including enrollment criteria
Potential future trial with Auxora in AKI to be evaluated after data analysis
... ► Artikel lesen | |
| 02.12.25 | Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial | 4 | Investing.com | ||
| 12.11.25 | CalciMedica, Inc.: CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 392 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026
Positive discussions with... ► Artikel lesen | |
| 06.11.25 | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.10.25 | CalciMedica partners with Telperian to use AI for clinical trial analysis | 1 | Investing.com | ||
| 14.10.25 | CalciMedica, Inc.: CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora | 215 | PR Newswire | AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials
LA JOLLA... ► Artikel lesen | |
| 12.08.25 | CalciMedica, Inc.: CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 224 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in early 2026
Productive initial meeting... ► Artikel lesen | |
| 14.05.25 | CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 215 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Presentations at... ► Artikel lesen | |
| 27.03.25 | CalciMedica, Inc.: CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates | 611 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Post-hoc analysis... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,60 | -0,75 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| MODERNA | 44,500 | -1,86 % | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| AMGEN | 330,00 | +0,44 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,412 | -1,94 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| STRYKER | 329,90 | +0,58 % | Think Surgical announces first TMINI robot cases with Stryker knee implant | ||
| BIOGEN | 161,00 | -0,83 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| ILLUMINA | 112,16 | -1,46 % | Evercore ISI reiterates Illumina stock rating on competitive positioning | ||
| VIKING THERAPEUTICS | 28,470 | -0,73 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,750 | +0,33 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 12,120 | +3,95 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 44,200 | -2,21 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,358 | -0,70 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,34 | -3,64 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,765 | -2,93 % | Sarepta Therapeutics, Inc. - 10-K, Annual Report | ||
| EXELIXIS | 34,290 | -8,07 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade |
Das Unternehmen CALCIMEDICA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -9,02 % bei einem Aktienkurs von 0,473 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.